Stock Movers

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Keurig Dr Pepper (KDP)  offered an upbeat forecast for its full-year sales, saying it expected a boost from its planned purchase of Dutch coffee maker JDE Peet’s NV later in 2026.
The soda and coffee company said it expected net sales between $25.9 billion and $26.4 billion for 2026, topping analysts’ expectations of $18.5 billion.

- Planet Fitness (PLNT) shares are down after the operator of fitness clubs gave an outlook for 2026 adjusted Ebitda growth that implies the profit measure will fall short of Wall Street expectations. 

- Hims & Hers Health (HIMS) shares fall on continued uncertainty about whether the telehealth company can keep selling copycat weight-loss drugs that are mired in legal and regulatory risks.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- Home Depot (HD) reported a key sales metric that beat expectations in the latest quarter on steady demand, though the retailer cautioned that macroeconomic challenges remain. Comparable sales, which track performance at locations open at least a year, rose 0.4% in the quarter ended Feb. 1, better than the average of estimates compiled by Bloomberg. Earnings per share, excluding some items, also outpaced expectations in the period.
- Paramount Skydance (PSKY) raised its offer to buy Warner Bros. Discovery (WBD), extending the long-running battle for one of Hollywood’s iconic studios, according to people familiar with the matter.The new, unspecified bid improves on the $30-a-share, all-cash proposal that Paramount took directly to Warner Bros. shareholders on Dec. 8 and addresses some of the company’s concerns with previous Paramount bids, according to the people, who asked to not be identified because the details aren’t public. Those concerns include greater certainty of Paramount financing.
- Keysight Technologies (KEYS) rise in trading after the company reported EPS and sales above estimate.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Standard Chartered announced a fresh $1.5 billion share buyback as it reported weaker-than-estimated fourth-quarter earnings, weeks after its share price was hit by the surprise departure of its chief financial officer.
- Telefónica posted fourth-quarter earnings that met analyst estimates as growth in Spain and Brazil offset weakness in other European markets.
- Unite plunged the most in more than four months after the UK student housing landlord’s full-year results showed a protracted slump in demand from international applicants.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
-  Novo Nordisk’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. 
- Fresenius Medical Care  fell after it posted a disappointing outlook where it expects broadly flat revenue and said profit could potentially decline this fiscal year.
- Telefónica posted fourth-quarter earnings that met analyst estimates as growth in Spain and Brazil offset weakness in other European markets.

See omnystudio.com/listener for privacy information.

On today's episode of Stock Movers:

- Shares of PayPal (PYPL) rose after a report suggested that its days as a standalone public company may be numbered, with its stock being described as "deeply undervalued" The company has fielded meetings with banks amid unsolicited interest from suitors, with at least one large rival looking at the whole company and others interested in certain PayPal assets.

- American Express (AXP) dragged the Dow Jones Industrial Average lower on Monday afternoon as investors responded to a bleak 2027 AI-driven recession scenario published by Citrini Research, a firm that offers thematic and global macro trading ideas.

- Domino’s Pizza Inc. shares jumped after the company reported a larger-than-expected rise in comparable sales, as consumers were drawn to the pizza chain’s budget-friendly pies. Domino’s US same-store sales for the fourth quarter rose 3.7% in the quarter, above the 3.3% increase projected by analysts, fueled by demand for its stuffed crust pizzas and its “Best Deal Ever” pizza promotion

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Emily Graffeo.

- IBM (IBM) shares plunged on Monday, after the artificial intelligence startup Anthropic said its Claude Code tool can help with modernizing COBOL, a dated programming language that’s mainly run on IBM computers. Shares sank 13% in their biggest one-day percentage loss since October 2000. With the decline, the stock is now down 27% in February, on track for its biggest one-month percentage decline since at least 1968, according to data compiled by Bloomberg.

-Arcellx (ACLX) shares surge as much as 78% — a record — to an all-time high after Gilead Sciences agreed to acquire the biotech company for $115 per share in cash and one contingent value right of $5 per share. Stifel views the deal as a “a near-term better-case scenario” for Arcellx.

DoorDash (DASH) stock slid Monday as investors reacted to a viral post from a research group describing the food-delivery company as a "poster child" for risks from AI agents. A company cofounder responded on X after the report sparked debate on the social media platform over the weekend.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

- Deere (DE) shares fall after Jefferies downgraded the company, saying the stock is pricing in a rebound in the farm economy that appears “elusive.” A downturn should reach its worst point this year, but analyst Stephen Volkmann says troughs have lasted years in the past and farmers face high costs and a volatile trade environment.

- Veris Residential (VRE) shares climb the most intraday since July 2023, after saying it will be acquired by an investor consortium led by Affinius Capital in partnership with Vista Hill Partners, in an all-cash transaction for $19 per share.

- Vanda Pharmaceuticals (VNDA) shares surge after the US FDA approved the firm’s oral medication for treating manic or mixed episodes in bipolar I disorder and schizophrenia in adults.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

-  Novo Nordisk (NVO) shares sink after its' next-generation obesity shot CagriSema delivered less weight loss than Eli Lilly & Co.’s rival blockbuster tirzepatide in a head-to-head trial.

- Domino's Pizza (DPZ) shares rise after the company reported a larger-than-expected rise in comparable sales, as consumers were drawn to the pizza chain’s budget-friendly pies. The Ann Arbor, Michigan-based company made more money by selling more food to its stores, charging higher prices for ingredients and collecting more fees from franchise operators for advertising and royalties, it said in a Monday statement. 

- International Paper (IP) shares fall as analysts note that a surprise price drop in domestic containerboard is negative for US packaging companies. 

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Gilead Sciences Inc. agreed to buy US cancer-focused biotech Arcellx Inc. for as much as $7.8 billion as it seeks to boost its drug pipeline. Gilead, which owns 11.5% of Arcellx’s outstanding stock, will pay $115 per share in cash, with a contingent payment of $5 per share dependent on future sales, it said Monday. The price is almost double Arcellx’s Friday closing price. Shares of Arcellx rose as much as 78% to $114.18 in premarket trading in New York, while Gilead’s stock slipped about 0.6%.

- Novo Nordisk A/S’s next-generation obesity shot delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Novo’s shares plunged as much as 16.5% in Copenhagen on Monday, while Lilly shares rose as much as 4.2% in premarket US trading.

- Domino's Pizza posted another quarter with strong comparable-sales growth and new restaurant openings, which sent the stock higher Monday. Still, shares have been trading at their lowest levels in more than two years as investors remain cautious about the restaurant sector. For the fourth quarter ended in December, the pizza chain grew its net revenue by 6.4% from a year ago to $1.54 billion, beating Wall Street's consensus expectations of $1.52 billion. Earnings came in at $5.35 per share, up 9.4% from a year earlier, but slightly below the expected $5.38, the company said Monday.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- Shares of Gilead Sciences (GILD) slipped in premarket trading after the company agreed to buy biotech firm Arcellx Inc. (ACLX) in a deal with an equity value of up to $7.8 billion as the US drugmaker seeks to boost its cancer drug pipeline. Gilead, which owns 11.5% of Arcellx’s outstanding stock, will pay $115 per share in cash, with a contingent payment of $5 per share dependent on future sales, according to a statement Monday. The price is almost double Arcellx’s closing price on Friday.
- Shares of Merck & Co. (MRK) rallied ahead of the US market open after the Wall Street Journal reported the company plans to split its main pharmaceutical unit in two as it prepares for the approaching patent expiry of its best-selling drug. The US drugmaker will separate its human-health division into a business that will house its cancer medications — including blockbuster immunotherapy Keytruda — and another for its non-cancer therapies, such as the HPV vaccine Gardasil, the newspaper reported.
- Shares of Domino's Pizza (DPZ) jumped premarket after the company reported a larger-than-expected rise in comparable sales, as consumers were drawn to the pizza chain’s budget-friendly pies. The Ann Arbor, Michigan-based company made more money by selling more food to its stores, charging higher prices for ingredients and collecting more fees from franchise operators for advertising and royalties, it said in a Monday statement.

See omnystudio.com/listener for privacy information.